JP2006518765A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518765A5
JP2006518765A5 JP2006503887A JP2006503887A JP2006518765A5 JP 2006518765 A5 JP2006518765 A5 JP 2006518765A5 JP 2006503887 A JP2006503887 A JP 2006503887A JP 2006503887 A JP2006503887 A JP 2006503887A JP 2006518765 A5 JP2006518765 A5 JP 2006518765A5
Authority
JP
Japan
Prior art keywords
hydrogen
substituted
lower alkyl
hydroxy
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518765A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/005755 external-priority patent/WO2004075856A2/en
Publication of JP2006518765A publication Critical patent/JP2006518765A/ja
Publication of JP2006518765A5 publication Critical patent/JP2006518765A5/ja
Pending legal-status Critical Current

Links

JP2006503887A 2003-02-24 2004-02-24 アデノシンa1受容体アンタゴニストを使って疾患を処置する方法 Pending JP2006518765A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US44995303P 2003-02-24 2003-02-24
US45049903P 2003-02-25 2003-02-25
US45050003P 2003-02-25 2003-02-25
US45132603P 2003-02-28 2003-02-28
US46481303P 2003-04-21 2003-04-21
US46481503P 2003-04-21 2003-04-21
US46481103P 2003-04-21 2003-04-21
US46481203P 2003-04-21 2003-04-21
PCT/US2004/005755 WO2004075856A2 (en) 2003-02-24 2004-02-24 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases

Publications (2)

Publication Number Publication Date
JP2006518765A JP2006518765A (ja) 2006-08-17
JP2006518765A5 true JP2006518765A5 (https=) 2007-02-22

Family

ID=32931788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503887A Pending JP2006518765A (ja) 2003-02-24 2004-02-24 アデノシンa1受容体アンタゴニストを使って疾患を処置する方法

Country Status (9)

Country Link
US (1) US20040229901A1 (https=)
EP (2) EP2087888A1 (https=)
JP (1) JP2006518765A (https=)
KR (1) KR20050106038A (https=)
AU (1) AU2004216133B2 (https=)
BR (1) BRPI0407494A (https=)
CA (1) CA2516730A1 (https=)
MX (1) MXPA05008805A (https=)
WO (1) WO2004075856A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011371A (es) * 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0509753A (pt) * 2004-04-16 2007-10-16 Novacardia Inc composição farmacêutica e método de tratamento de doença cardiovascular
CA2947335A1 (en) 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
BRPI0821483A2 (pt) * 2007-12-27 2015-06-16 Bayer Animal Health Gmbh Tratamento de doença cardíaca usando beta-bloqueadores
US11291641B2 (en) * 2016-10-03 2022-04-05 The Children's Medical Center Corporation Prevention and treatment of diabetic nephropathy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) * 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
AU2297192A (en) * 1991-06-28 1993-01-25 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
EP0541120B1 (en) * 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995031460A1 (en) * 1994-05-17 1995-11-23 Kyowa Hakko Kogyo Co., Ltd. Process for producing xanthine derivative
CN1049117C (zh) * 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
US6254889B1 (en) * 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE281835T1 (de) * 1996-08-07 2004-11-15 Kyowa Hakko Kogyo Kk Fettemulsion, die ein xanthinderivat enthält
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US20020115687A1 (en) * 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
CN100390178C (zh) * 1999-11-12 2008-05-28 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
MXPA02004795A (es) * 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
US20050038017A1 (en) * 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
US20040235809A1 (en) * 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
BR0115833A (pt) * 2000-12-01 2003-10-28 Biogen Inc Derivados condensados de purina como antagonistas de receptores de adenosina a1
HUP0302455A3 (en) * 2000-12-18 2005-05-30 Novartis Ag Combination pharmaceutical compositions containing amplodipine and benazepril and their use
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
MXPA05011371A (es) * 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
US20050239758A1 (en) * 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
CA2565037A1 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
EP2035092A2 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
EP2061793A2 (en) * 2006-08-22 2009-05-27 Novacardia, Inc. Kw-3902 conjugates that do not cross the blood-brain barrier

Similar Documents

Publication Publication Date Title
JP2006518765A5 (https=)
JP2005053931A5 (https=)
JP2005532287A5 (https=)
JP2008510828A5 (https=)
JP2004530641A5 (https=)
JP2001525411A5 (https=)
JP2004533444A5 (https=)
JP2010534247A5 (https=)
JP2013505929A5 (https=)
JP2009538336A5 (https=)
JP2010530897A5 (https=)
JP2006521359A5 (https=)
JP2013514980A5 (https=)
JP2004501940A5 (https=)
JP2010501478A5 (https=)
WO2004020430A3 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
JP2004131511A5 (https=)
JP2004504323A5 (https=)
JP2019516720A5 (https=)
JP2004527567A5 (https=)
JP2004529953A5 (https=)
JP2002506864A5 (https=)
JP2010534246A5 (https=)
JP2008545718A5 (https=)
JP2003507380A5 (https=)